Related by context. All words. (Click for frequent words.) 68 RDEA# 68 nitazoxanide 67 PEG Interferon lambda 66 INCB# [001] 66 ANA# 66 Phase 1b trial 65 Phase 1b 65 ganetespib 65 ITMN 65 oral prodrug 65 Phase Ib 65 phase IIb 65 HGS ETR1 64 PRT# 64 HuMax CD# 64 JAK inhibitor 64 elotuzumab 64 Sym# 64 Actilon 64 preclinical studies 64 PSN# [002] 64 ISIS # 64 multiple ascending dose 64 PEG SN# 63 Phase 2a trial 63 bevirimat 63 telbivudine 63 administered subcutaneously 63 Phase 1a clinical 63 valopicitabine 63 XL# [003] 63 Traficet EN 63 huC# DM4 63 antiviral activity 63 pomalidomide 63 Phase 2a 63 preclinical 63 SCH # 62 OXi# 62 dacetuzumab 62 R#/MEM # 62 Phenoptin 62 NGX# 62 alvespimycin 62 RGB # 62 non nucleoside HCV 62 ALKS 62 Laquinimod 62 daclizumab 62 evaluating tivozanib 62 TRIOLEX 62 phase IIa clinical 62 axitinib 62 Phase 2b trial 62 lomitapide 62 Dapagliflozin 62 MGCD# [001] 62 Phase 1a 62 Phase Ib study 62 PRX # 62 celgosivir 62 LymphoStat B 62 ocrelizumab 62 MAXY alpha 62 phase 2a 62 laquinimod 62 phase IIa 62 Amigal 62 forodesine 61 favorable pharmacokinetic profile 61 pradefovir 61 HGS ETR2 61 HuMax EGFr 61 Phase IIb 61 integrase inhibitor 61 rindopepimut 61 bendamustine 61 Phase 1b clinical 61 HEPLISAV 61 ALN RSV# 61 CRx 61 TMC# [001] 61 ARRY 61 talactoferrin 61 tezampanel 61 Phase 2b study 61 Phase IIb trials 61 PF # [001] 61 ongoing Phase 1b 61 Phase IIa trial 61 nucleotide analog 61 albinterferon alfa 2b 61 Pegasys plus Copegus 61 nonclinical studies 61 TELCYTA 61 AVN# [001] 61 SAR# [004] 61 Nasulin 61 INCB# [002] 61 Zerenex 61 HspE7 61 phase IIb clinical 61 tgAAC# 61 Phase Ib clinical 61 eltrombopag 61 PEG PAL 61 TELINTRA 61 teriflunomide 61 TMC# [002] 61 PS# [001] 61 Phase IIa clinical 61 INGN 61 Phase 2a clinical 61 SparVax TM 61 CEQ# 60 BCX# 60 dose cohorts 60 apremilast 60 teduglutide 60 eniluracil 60 mipomersen 60 Triolex 60 ascending doses 60 Valortim 60 vicriviroc 60 ISENTRESS 60 decitabine 60 TOCOSOL Paclitaxel 60 neratinib 60 trodusquemine 60 PXD# 60 orally dosed 60 HuMax CD4 60 virus HCV protease inhibitor 60 CORT # 60 PDE4 inhibitor 60 refractory gout 60 mcg dose 60 CCR5 antagonist 60 darunavir ritonavir 60 polymerase inhibitor 60 HCV protease inhibitor 60 viral kinetic 60 XmAb# 60 AP# [003] 60 Phase IIb trial 60 BRIM3 60 NKTR 60 huN# DM1 60 telaprevir VX 60 Genz # 60 placebo controlled Phase 60 atacicept 60 ZYBRESTAT 60 visilizumab 60 oral bioavailability 60 posaconazole 60 subcutaneous formulation 60 ADX# 60 ENMD # 60 ALTU 60 Plicera 60 AVE# 60 selective androgen receptor modulator 60 dosing cohort 60 GALNS 60 Androxal TM 60 denufosol 60 metaglidasen 60 subcutaneously administered 60 carfilzomib 59 Omacetaxine 59 LY# [003] 59 dose cohort 59 CYT# 59 Protexia R 59 solithromycin 59 Albuferon 59 Phase #/#a 59 PD LID 59 urocortin 2 59 tolerability profile 59 AEZS 59 cannabinor 59 HCD# [002] 59 tivozanib 59 RSD# 59 CIMZIA TM 59 Phase 2b clinical 59 vidofludimus 59 Zalbin 59 amrubicin 59 docetaxel chemotherapy 59 dimebon 59 otelixizumab 59 PRTX 59 CG# [003] 59 HuLuc# 59 OncoVEX GM CSF 59 maribavir 59 pharmacokinetic PK study 59 PROMACTA 59 CRLX# 59 Phase Ia 59 DEB# 59 Locteron 59 entinostat 59 Blinatumomab 59 AEGR 59 pharmacokinetic studies 59 Ostarine 59 Valortim ® 59 Azixa 59 phase Ib 59 raltegravir 59 Aptivus ® 59 voreloxin 59 CR# vcMMAE 59 mg kg dose 59 Archexin 59 rFIXFc 59 Anthim 59 arimoclomol 59 oral methylnaltrexone 59 MDV# 59 Cethromycin 59 maraviroc 59 mertansine 59 Phase IIb clinical 59 Bezielle 59 CDP# 59 HGS# 59 Allovectin 7 ® 59 Phase IIa trials 59 Reverset 59 perifosine 59 Thiovir 59 lesinurad 59 single ascending dose 59 Pegasys ® 59 Marqibo 59 NU# [001] 59 XL# anticancer compounds 59 pafuramidine 59 BAY #-# 59 treatment naïve genotype 59 viral kinetics 58 HCV polymerase inhibitor 58 danoprevir 58 ALN VSP 58 preclinical efficacy 58 nucleoside 58 ASONEP 58 AZILECT R 58 dose escalation study 58 uric acid lowering 58 maximally tolerated dose 58 MLN# 58 investigational oral 58 Tarceva TM 58 oral FTY# 58 Apoptone 58 vilazodone 58 transcriptase inhibitor NNRTI 58 LCP Tacro 58 non nucleoside inhibitor 58 RG# [001] 58 velafermin 58 sapacitabine 58 OHR/AVR# 58 Mipomersen 58 radezolid 58 GAMMAGARD 58 JAK2 inhibitor 58 APTIVUS r 58 potent antiviral 58 bardoxolone methyl 58 DAVANAT 58 DB# [003] 58 Capesaris 58 chronic HCV infection 58 systemically administered 58 oral rivaroxaban 58 Oral NKTR 58 pharmacokinetic PK profile 58 betrixaban 58 KRN# 58 preclinical pharmacokinetic 58 Forodesine HCl 58 NVA# 58 custirsen 58 daptomycin 58 obatoclax 58 pralatrexate 58 Serdaxin 58 ascending dose 58 RSD# oral 58 SELZENTRY 58 midstage clinical 58 dose escalation trial 58 pharmacokinetic 58 Viramidine 58 CCX# 58 Phase 2a clinical trials 58 Phase III clinical trials 58 ARIKACE 58 Ophena TM 58 lixisenatide 58 ATHX 58 oral dosing 58 liposomal formulation 58 Phase IIa 58 Allovectin 7 R 58 liprotamase 58 Heplisav 58 HCV protease inhibitors 58 iSONEP 58 MAXY G# 58 APTIVUS 58 anakinra 58 TG# [003] 58 Phase 2b 58 Asentar 58 MAP# 58 mGluR5 NAM 58 dyskinesia PD LID 58 Phase III clinical 58 hGH CTP 58 ALN TTR# 58 investigational protease inhibitor 58 rHuPH# 58 tolerability 58 preclinically 58 PREZISTA r 58 diabetic neuropathic pain 58 deforolimus 58 calcitonin 58 atazanavir ritonavir 58 bicifadine 58 oral antiviral 58 IIa trial 58 CBLB# 58 ritonavir boosted 58 GRN#L 58 lintuzumab 58 Panzem R 58 TACI Ig 58 insulin degludec 58 treatment naive genotype 58 Elotuzumab 58 LymphoStat B TM 58 ruxolitinib 58 Pradefovir 58 ELND# 58 adecatumumab MT# 57 pharmacodynamic 57 glufosfamide 57 pharmacokinetic pharmacodynamic 57 nucleoside analog 57 romiplostim 57 confirmatory Phase 3 57 Ocrelizumab 57 Symadex 57 Interferon alpha 57 elagolix 57 tremelimumab 57 Tarvacin TM 57 IMGN# 57 ofatumumab 57 viral suppression 57 IND enabling 57 Phase Ib II 57 EOquin 57 methylnaltrexone 57 dose limiting toxicities 57 Carfilzomib 57 desvenlafaxine succinate 57 TBC# 57 MT# MEDI 57 HCV infected 57 ANAVEX #-# [003] 57 blinatumomab 57 VLP vaccine 57 peginterferon alfa 2b 57 QLT# 57 Relivar 57 Clevudine 57 Tyrima 57 Neurodex 57 Phase III trials 57 ORMD 57 elvitegravir 57 TDF FTC 57 Quinamed 57 CCR5 mAb 57 DXL# 57 safety tolerability pharmacokinetic 57 antiviral efficacy 57 telaprevir 57 AEG# 57 torezolid phosphate 57 TRX1 57 alagebrium 57 aleglitazar 57 Phase IIIb clinical 57 Phase IIB 57 QNEXA 57 enzastaurin 57 canakinumab 57 Dasatinib 57 Panzem 57 SILENOR TM 57 Vitaxin 57 Panzem R NCD 57 riociguat 57 Trizytek 57 plus ribavirin 57 tolerability profiles 57 ritonavir boosting 57 mapatumumab 57 Phase Ib clinical trials 57 TYZEKA 57 pharmacokinetic PK 57 GSK# [001] 57 S/GSK# 57 tenofovir emtricitabine 57 Nuvion 57 elacytarabine 57 MAGE A3 ASCI 57 DermaVir Patch 57 trastuzumab DM1 T DM1 57 Dacogen injection 57 elesclomol 57 GLP toxicology studies 57 IMC A# 57 XL# XL# 57 Vaxfectin 57 #D#C# 57 adalimumab 57 TKM ApoB 57 HQK 57 Amplimexon 57 PEGylated 57 R# #mg BID 57 adefovir 57 blinded randomized placebo controlled 57 stated Michelle Berrey 57 picoplatin 57 #th Annual Interscience 57 clinical trial 57 ponatinib 57 rilonacept 57 ataluren 57 tramiprosate Alzhemed TM 57 Cimzia ® 57 lumiliximab 57 pharmacokinetics PK 57 NEUGENE 57 ICA # 57 pharmacodynamic properties 57 Daclizumab 57 EndoTAG TM -1 57 Glufosfamide 57 Civacir 57 humanized anti 57 LY# [002] 57 dosing cohorts 57 CA4P 57 BiTE R 57 ulimorelin 57 pramlintide 57 XL# XL# XL# XL# 57 DU #b 57 HCV 57 tanespimycin 57 squalamine 57 CoFactor 57 RhuDex ® 57 demonstrated antitumor activity 57 FluCide 57 bazedoxifene 57 targeting CD# 56 TransVax TM 56 Telbivudine 56 rNAPc2 56 Adalimumab 56 midstage trials 56 Excellarate 56 Allovectin 7 56 KNS # 56 TRO# 56 octreotide acetate 56 MultiStem 56 Tarvacin 56 Excellarate TM 56 Exelixis compounds 56 darapladib 56 oral ridaforolimus 56 peg IFN 56 relapsed multiple myeloma 56 PEGPH# 56 interferon IFN 56 dacetuzumab SGN 56 YONDELIS 56 FTY# 56 Ramoplanin 56 AzaSite Plus 56 rilpivirine 56 cidofovir 56 docetaxel Taxotere ® 56 Factor VIIa 56 Imprime PGG 56 monotherapy 56 GLPG# 56 volociximab 56 GSK # 56 vosaroxin 56 RiVax 56 Pimavanserin 56 lamivudine 56 Seliciclib 56 phase IIb study 56 Initiate Phase 56 ixabepilone 56 HCV SPRINT 56 Peg IFN 56 PEGASYS ® 56 omega interferon 56 GLYX 56 anti leukemic 56 cilengitide 56 Bortezomib 56 Xanafide 56 pegylated interferon alpha 56 Elvitegravir 56 multicenter Phase 56 CTA# Injection 56 LEXIVA 56 Fx #A 56 MEK inhibitor 56 Linjeta ™ 56 elvucitabine 56 lintuzumab SGN 56 Phase #b/#a 56 nucleotide analogue 56 relapsing remitting multiple sclerosis 56 Phase #b/#a trial 56 novel VDA molecule 56 BRIM2 56 RhuDex 56 cMET 56 Phase 2b clinical trials 56 MEK inhibitor RDEA# 56 dexpramipexole 56 retapamulin 56 TriRima 56 GeoVax vaccine 56 tezampanel NGX# 56 investigational pan BCR 56 XOMA 3AB 56 HEPLISAV TM 56 immunomodulator 56 Multimeric 56 ENBREL 56 ISTODAX 56 Alzhemed TM 56 alefacept 56 pegylated 56 OncoVEX 56 ImmunoVEX HSV2 56 investigational compound 56 PANVAC VF 56 NOX E# 56 Perifosine 56 AMD# [002] 56 MERLIN TIMI 56 Homspera 56 Proellex 56 CK # 56 H#N# VLP vaccine 56 pivotal Phase III 56 Randomized Phase 56 mcg kg 56 Protectan CBLB# 56 INT# [002] 56 Linagliptin 56 Valortim R 56 carcinogenicity study 56 pertuzumab 56 Restanza 56 ORENCIA R 56 dose escalation Phase 56 sitagliptin 56 intranasal formulation 56 RAPTIVA 56 Corlux 56 pemetrexed Alimta 56 nanoviricides 56 Parkinson disease levodopa induced 56 muraglitazar 56 selective modulator 56 BioVant 56 Posiphen 56 alemtuzumab MS 56 Telintra 56 alicaforsen enema 56 Revimmune 56 PDX pralatrexate 56 Indibulin 56 avanafil 56 CUDC 56 LibiGel Phase III 56 placebo controlled clinical trials 56 VEGF inhibitor 56 oritavancin 56 ARCALYST 56 LAF# 56 ostarine 56 EOquin TM 56 orally administered 56 forodesine hydrochloride 56 APD# 56 cathepsin K inhibitor 56 bosutinib 56 R roscovitine 56 inecalcitol 56 nab paclitaxel 56 ocular formulation 56 VIRAMUNE XR 56 mg dose 56 LibiGel ® 56 talabostat 56 sunitinib malate 56 bifeprunox 56 boosted protease inhibitor 56 peginterferon alpha 2a 56 Anturol 56 MVA BN R 56 AZX# 56 CD# monoclonal antibody 56 PLK1 SNALP 56 clinical pharmacology studies 56 Menerba 56 Locteron ® 56 Viread Emtriva 56 orBec 56 PROSTVAC VF 56 JANUVIA 56 Teriflunomide 56 confirmatory Phase III 56 Cinryze ™ 56 relapsed MM 56 seliciclib 56 Androxal 56 Urocortin 2 56 subcutaneous injections 56 OMP #M# 56 pegylated interferon alfa 2a 56 omecamtiv mecarbil 56 Phase IIa clinical trials 56 alvimopan 56 pharmacodynamic profile 56 randomized Phase 56 INTELENCE 56 orally bioavailable 56 registrational trial 56 CORLUX 56 IMP# 56 replicon 56 class mGluR5 inhibitor 56 vitro studies 56 HCV protease 56 CELVAPAN H#N# 56 milatuzumab 56 febuxostat 56 compound INCB# 56 Zenvia Phase III 56 Technosphere Insulin 56 baminercept 55 odanacatib 55 Maribavir 55 veltuzumab 55 antitumor activity 55 pharmacokinetic profile 55 Telaprevir 55 DR Cysteamine 55 CD# CEA 55 alpha 2a 55 casopitant 55 NXL# 55 Hematide 55 Phase III confirmatory 55 GSK# [002] 55 Eltrombopag 55 Cloretazine ® 55 ROTARIX 55 cethromycin 55 preclinical toxicology 55 investigational monoclonal antibody 55 PROSTVAC TM 55 IRX 2 55 HCV NS5B polymerase 55 Q#IR 55 MEK inhibitors 55 metreleptin 55 paliperidone ER 55 SIV infection 55 varespladib 55 REMUNE R 55 orally administered inhibitor 55 Cethrin 55 tipranavir 55 Veronate 55 Azedra 55 lenalidomide Revlimid R 55 DDP# 55 Pharmacokinetics PK 55 zalutumumab 55 Fodosine 55 APOPTONE 55 #mg dose [001] 55 ZOLINZA 55 mg RDEA# 55 GVAX 55 proteasome inhibitor 55 PHX# 55 Trexima 55 sulodexide 55 PegIFN RBV 55 ridaforolimus 55 ribavirin RBV 55 VICTOR E1 55 mg BID 55 phase Ib clinical 55 Ophena 55 non nucleoside 55 GRN# 55 vemurafenib 55 MB# [004] 55 pegylated interferon 55 fostamatinib 55 MAA submission 55 CGEN # 55 IMC #B 55 Bicifadine 55 tenofovir Viread 55 FOLOTYN 55 BYDUREON 55 multicenter Phase II 55 reslizumab 55 R#/MEM 55 MGCD# [002] 55 peginterferon 55 bardoxolone 55 IFN α 55 ProSavin 55 dextromethorphan quinidine 55 Zavesca R 55 tafamidis 55 registrational 55 CYC# 55 Golimumab 55 RH1 55 ATL/TV# 55 oxymorphone ER 55 LymphoStat B belimumab 55 bortezomib 55 CIMZIA ™ 55 Alocrest 55 dose escalation clinical 55 investigational humanized monoclonal antibody 55 pexiganan 55 sodium glucose cotransporter 55 dose escalation phase 55 Tanespimycin 55 Hyphanox 55 EVIZON 55 enfuvirtide 55 avosentan 55 pre exposure prophylaxis 55 Initiated Phase 55 #I TM# 55 Cimzia R 55 BLA filing 55 brivaracetam 55 fosbretabulin 55 PI3K inhibitor 55 rFVIIIFc 55 TASKi2 55 tasimelteon 55 Antiviral Activity 55 Albuferon TM 55 lanthanum carbonate 55 μg dose 55 docetaxel Taxotere R 55 investigational drug 55 interferon alfa 55 Shigamabs ® 55 Tezampanel 55 ACTEMRA 55 mcg doses 55 Hsp# Inhibitor 55 albiglutide 55 iclaprim 55 Talabostat 55 virologic 55 Preclinical studies 55 entecavir 55 Prodarsan ® 55 Aurora kinase inhibitor 55 cobiprostone 55 phase IIb trial 55 ACZ# 55 Hsp# inhibitors 55 ProLindac 55 Arimoclomol 55 Taspoglutide 55 polymerase inhibitors 55 Zalypsis 55 Solulin 55 teplizumab 55 Aurexis 55 Zolinza 55 mg/m2 dose 55 bortezomib Velcade 55 nucleoside reverse transcriptase inhibitor 55 tamibarotene 55 atazanavir sulfate 55 Phase III 55 Tesetaxel 55 SinuNase TM 55 pharmacodynamic PD 55 darusentan 55 romidepsin 55 Tamibarotene 55 bafetinib 55 ELACYT 55 sorafenib Nexavar 55 Fibrillex TM 55 postoperative ileus POI 55 CBLC# 55 CYT# potent vascular disrupting 55 Arikace 55 clinical trials 55 aflibercept 55 samalizumab 55 Zoraxel 55 MYDICAR 55 vivo efficacy 55 azilsartan medoxomil 55 anticancer activity 55 VRX# [002] 55 multicenter Phase III 55 PNP inhibitor 55 evaluating mipomersen 55 HBeAg positive 55 BiTE antibody 55 ancrod 55 injectable formulation 55 Phase II 55 PEARL SC 55 davunetide intranasal AL 55 double blinded randomized 55 sustained virologic response 55 Atrasentan 55 Targretin 55 Phase IIb Trial 55 NOXAFIL 55 VAPRISOL 55 chronic hepatitis C 55 abacavir lamivudine 55 Lisofylline LSF 55 long acting muscarinic 55 Velcade bortezomib 55 ALD# 55 thymalfasin 55 IMA# 55 AGILECT R 55 Anadys 55 rALLy trial 55 Adentri 55 panitumumab 55 GW# [003] 55 VivaGel TM 55 Darusentan 55 Linaclotide 55 immunomodulatory 55 angiogenesis inhibitor 55 MNTX 55 JAK1 55 rhC1INH 54 adipiplon 54 Diamyd ® 54 pharmacokinetic properties 54 ceftazidime 54 budesonide foam 54 ritonavir boosted protease inhibitor 54 GFT# 54 aurora kinase 54 Altastaph 54 XL# SAR# 54 mg QD 54 NNRTI 54 placebo controlled 54 anti TNF alpha 54 linaclotide 54 2 methoxyestradiol 54 PREZISTA rtv 54 PEG IFN 54 PREZISTA 54 RAPAFLO 54 SPC# [001] 54 ramelteon 54 nucleoside analogues 54 sorafenib tablets 54 amprenavir 54 faropenem 54 marketed pegylated interferons 54 BARACLUDE ® 54 BMS # 54 Board DSMB 54 ibandronate 54 tipifarnib 54 protease inhibitor 54 urate lowering 54 pramlintide metreleptin 54 PSMA ADC 54 farletuzumab 54 crizotinib PF # 54 cancer neuroendocrine tumor 54 metastatic castration resistant 54 oral protease inhibitor 54 Chemophase 54 antiviral potency 54 telaprevir dosed 54 alfa 2a 54 administered orally 54 ritonavir boosted danoprevir 54 peg interferon 54 pegylated interferons 54 randomized Phase 2b 54 Anidulafungin 54 indacaterol 54 Nexavar ® 54 Nanobody 54 Annamycin 54 Romidepsin 54 synthetic retinoid 54 protein kinase inhibitor 54 NLX P# 54 isatoribine 54 hematological cancers 54 VELCADE melphalan 54 Epivir 54 eliglustat tartrate 54 VEGF Trap 54 Ridaforolimus 54 SAR# [002] 54 TYKERB 54 Varespladib 54 Phase IIb clinical trials 54 metformin sulfonylurea 54 MIRCERA 54 exenatide 54 Acetavance 54 AVP #D# 54 placebo controlled clinical 54 iCo 54 RLY# 54 bavituximab 54 DAS# [001] 54 dapagliflozin 54 PEG interferon 54 Pazopanib 54 NEUGENE antisense 54 ZFP Therapeutic 54 TLK# 54 perampanel 54 Cleviprex TM clevidipine 54 DexaSite 54 TPI ASM8 54 Entereg R 54 EDEMA3 54 JAK inhibitors 54 Sphingomab 54 Linjeta TM 54 Unit Dose Budesonide 54 ABILIFY ® 54 AZT zidovudine Retrovir 54 NV1FGF 54 Sebivo 54 PENNVAX B 54 AERx iDMS 54 aclidinium 54 GetGoal Phase III 54 TG# [001] 54 tolevamer 54 ZD# [001] 54 Idenix